Correction In the February 2023 issue of Evidence-Based GI, the title of the article on dupilumab incorrectly referred to it…
Correction
Posted on March 14, 2023
Endoscopic Sleeve Gastroplasty Is Effective for Patients with Obesity Who MERIT Intervention
Posted on February 21, 2023
Endoscopic Sleeve Gastroplasty Is Effective for Patients With Obesity Who MERIT Intervention Jennifer M. Kolb MD, MS1 and Austin L.…
Dupilumab, an IgG4 Monoclonal Antibody, for Eosinophilic Esophagitis: Revising the Treatment Paradigm
Posted on
Dupilumab, an IgG4 Monoclonal Antibody, for Eosinophilic Esophagitis: Revising the Treatment Paradigm Afrin Kamal, MD, MS1 and Philip Schoenfeld, MD,…
Direct-Acting Antiviral Therapy for Hepatitis C Virus Decreases All-Cause Mortality and Decompensated Cirrhosis: Treat (Virtually) Everyone
Posted on
Direct-Acting Antiviral Therapy for Hepatitis C Virus Decreases All-Cause Mortality and Decompensated Cirrhosis: Treat (Virtually) Everyone Philip Schoenfeld, MD, MSEd,…
Early Colonoscopy for Acute Lower GI Bleeding Usually Is Not the Answer
Posted on
Early Colonoscopy for Acute Lower GI Bleeding Usually Is Not the Answer Shria Kumar, MD, MSCE Assistant Professor, Division of…
Risankizumab, an Interleukin-23 Inhibitor, for Moderate-Severe Crohn’s Disease: Advancing Care Beyond Anti-TNF Therapy
Posted on January 25, 2023
ACG EBGI: This Evidence-based summary looks at D’Haens G, Panaccione R, Baert F, et al. Risankizumab as Induction Therapy for Crohn’s Disease: Results from the Phase 3 ADVANCE and MOTIVATE Induction Trials. Lancet 2022;399(10340):2015-30.
Subcutaneous risankizumab is effective and safe for the maintenance of moderate-to-severe Crohn’s disease
Posted on
ACG EBGI: Evidence-based summary reviews Ferrante M, Panaccione R, Baert F, et al. Risankizumab as maintenance therapy for moderately to severely active Crohn’s disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal Phase 3 FORTIFY maintenance trial. Lancet 2022;399(10340):2031-2046.
When It’s Not Acid Reflux: Managing PPI-Resistant GERD Patients Based on Bravo Results
Posted on
Evidence-based summary reviews Yadlapati R, Gyawali CP, Masihi M, et al. Optimal Wireless Reflux Monitoring Metrics to Predict Discontinuation of Proton Pump Inhibitor Therapy. Am J Gastroenterol. 2022 Oct 1;117(10):1573-1582. doi.org/10.14309/ajg.0000000000001871.
ICYMI: Is Terlipressin for the Treatment of Hepato-Renal Syndrome Ready for Primetime: Results of the CONFIRM Trial
Posted on
This summary reviews Wong F, Pappas SC, Curry MP, et al. Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome. N Engl J Med. 2021 Mar 4;384(9):818-828.
Ozanimod for Moderate-Severe Ulcerative Colitis: Re-Thinking the Top-Down Treatment Algorithm for UC
Posted on December 14, 2022
Ozanimod for Moderate-Severe Ulcerative Colitis: Rethinking the Top-Down Treatment Algorithm Oriana Damas, MD1 and Philip Schoenfeld, MD, MSEd, MSc (Epi)2…